SSRIs & Antidepressants
Selective Serotonin Reuptake Inhibitors (SSRIs) are the most commonly prescribed antidepressants and one of the most important interaction categories for psychedelic use.
SSRI + Psilocybin / LSD
- •Reduced effects: SSRIs typically diminish or block the effects of classical psychedelics because both compete for serotonin receptor binding sites.
- •Unpredictable intensity: Some individuals report normal or even heightened effects despite SSRI use, making the interaction unpredictable.
- •Do NOT stop SSRIs abruptly: Discontinuing SSRIs to "make psychedelics work" is dangerous. SSRI withdrawal can cause serious symptoms and psychiatric destabilization.
SSRI + MDMA — DANGEROUS
- •Serotonin syndrome risk: Combining MDMA with SSRIs can trigger serotonin syndrome — a potentially life-threatening condition characterized by hyperthermia, muscle rigidity, rapid heart rate, and seizures.
- •Reduced MDMA effects + increased danger: SSRIs may block the empathogenic effects while still leaving the physiological risks, potentially leading to redosing and further danger.
MAOIs — Highest Risk Category
Monoamine Oxidase Inhibitors (MAOIs) represent the most dangerous interaction category. MAOIs are found in certain antidepressants (phenelzine, tranylcypromine, isocarboxazid) and in ayahuasca brews (harmine, harmaline).
- •MAOI + MDMA: EXTREMELY DANGEROUS. Can cause fatal serotonin syndrome and hypertensive crisis. This combination has resulted in deaths.
- •MAOI + Psilocybin: Dramatically intensifies and extends the experience. Can produce overwhelming, unmanageable states. Not recommended outside of traditional ayahuasca contexts with experienced facilitators.
- •MAOI + Stimulants: Risk of hypertensive crisis (dangerous blood pressure spikes).
Lithium — Serious Documented Risk
Published case reports associate lithium combined with classical psychedelics (psilocybin, LSD, mescaline) with severe adverse events. Case reports cannot determine an individual outcome, but the reported risk supports avoiding the combination.
- •Reports of seizures, cardiac complications, and prolonged psychotic episodes when combined with LSD or psilocybin.
- •This interaction is considered one of the most dangerous in psychedelic harm reduction.
- •Do not use classical psychedelics if you are taking lithium.
Other Medication Interactions
- •SNRIs (venlafaxine, duloxetine): Similar to SSRIs — may reduce psychedelic effects. Serotonin syndrome risk with MDMA. Do not discontinue abruptly.
- •Tricyclic antidepressants: May intensify or unpredictably alter psychedelic effects. Serotonergic interaction risk.
- •Benzodiazepines (Xanax, Valium): May reduce psychedelic effects and are sometimes used by clinicians in emergencies. Available evidence does not establish that unsupervised combination is safe.
- •Antipsychotics: Block 5-HT2A receptors and will likely prevent psychedelic effects entirely. Can be used to terminate a psychedelic experience in emergencies.
- •Tramadol: Lowers seizure threshold. Risk of serotonin syndrome when combined with MDMA or ayahuasca. Avoid combination.
- •Blood pressure medications: Psychedelics can affect blood pressure. Ketamine raises BP; MDMA raises BP and heart rate. Consult your prescribing physician.
Medical Conditions
- •Cardiovascular conditions: Psychedelics can increase heart rate and blood pressure. Those with heart conditions, uncontrolled hypertension, or history of stroke should exercise extreme caution. MDMA poses the highest cardiovascular risk.
- •Psychotic spectrum disorders: Personal or family history of schizophrenia, schizoaffective disorder, or psychotic episodes is a strong contraindication for all psychedelics. They can trigger first episodes or worsen existing conditions.
- •Bipolar disorder: Risk of triggering manic episodes. Some researchers believe carefully controlled psilocybin may eventually be studied for bipolar depression, but current evidence is insufficient.
- •Seizure disorders: Some psychedelics may lower seizure thresholds. Discuss with a neurologist.
- •Pregnancy: Insufficient safety data exists. Psychedelics should be avoided during pregnancy and breastfeeding.
- •Liver conditions: Psilocybin is metabolized by the liver. Severe liver disease may affect metabolism and increase risk.
Quick Reference Table
| Medication | + Psilocybin/LSD | + MDMA |
|---|---|---|
| SSRIs | Reduced effects | Serotonin syndrome risk |
| MAOIs | Extreme intensification | FATAL RISK |
| Lithium | Seizures/cardiac risk | Dangerous |
| Benzodiazepines | Reduces effects | Reduces effects |
| Antipsychotics | Blocks effects | May reduce effects |
| Tramadol | Seizure risk | Serotonin syndrome risk |